Articles

2008: The Debates

A series of debates on the most relevant, and most controversial, topics in ophthalmology, in which today's most eminent ophthalmologists argue for the validity of their differing opinions and practices.

HOYA Surgical Optics has been distributing IOLs to ophthalmic surgeons in Europe since 2003. The name HOYA, however, represents more than just IOLs; the firm has a long tradition in high tech optics…

The Phase I three-year feasibility study of the Argus II Retinal Implant for Retinitis Pigmentosa (RP) will be expanded to enrol more patients in Europe, according to an announcement from Second Sight Medical Products, the implant's manufacturer.

An ophthalmology network, aiming to prevent loss of vision across the country, has been established in Wales.

The growing understanding that glaucoma is a neurodegenerative rather than ocular disease is to be the principal topic of discussion of the annual Glaucoma Research Foundation (GRF) benefit, to be held January 28 2009 in San Francisco, California, US.

STAAR Surgical has created the Collamer Accommodating Study Team (CAST), a group of seven ophthalmologists who will investigate the accommodative properties of STAAR's Collamer intraocular lens (IOL).

The Phase IIb trial assessing the safety and efficacy of microplasmin in patients, showed complete resolution of vitreomacular traction or macular hole without need for vitrectomy surgery, according to a statement from the trial sponsor, ThromboGenics NV.

Contact anaesthesia is just as safe and effective as peribulbar application for combined cataract and glaucoma surgery, according to study results published online ahead of print by Ophthalmologica.

Performing selective laser trabeculoplasty (SLT) in patients with pseudoexfoliative glaucoma (PEXG) may in fact cause a rise in intraocular pressure (IOP), according to results published in the October issue of BMC Ophthalmology.

Ellex's 2RT, a Retina Regeneration Therapy, is safe and effective in the treatment of macular oedema (ME) secondary to diabetic retinopathy (DR), according to study results presented at this year's American Academy of Ophthalmology meeting.

Following limited reports of adverse events encountered by US physicians using a particular batch of Healon D viscoelastic, AMO has recalled the remaining products in the batch.

Shunt reimbursement amended

The level of reimbursement of Optonol's Ex-PRESS Mini Glaucoma Shunt has been increased by the US Centers for Medicare and Medicaid (CMS), according to an announcement made by Optonol at the Glaucoma Subspecialty Day of this year's meeting of the American Academy of Ophthalmology.

A Phase I trial of POT-4, a complement inhibitor in development for the treatment of age-related macular degeneration (AMD), have demonstrated that the agent is safe and well tolerated. The results were presented by Potentia Pharmaceuticals during the Retina Subspecialty Day at the meeting of the American Academy of Ophthalmology.

The Latanoprost punctal plug drug delivery system (L-PPDS) has performed well in its Phase II CORE trial, according to study data released by the manufacturer, QLT Plug Delivery Inc.

The introduction of anti-glaucoma medications has reduced the need for filtration surgery, according to study results published online ahead of print by Eye.

The Implantable Miniature Telescope (IMT) from VisionCare for end-stage age-related macular degeneration (AMD) maintains best-corrected visual acuity (BCVA) improvements to two years, according to results published in the November edition of the American Journal of Ophthalmology.